I hesitate to even show the article, but I will give the URL and you can go see for yourself. I will share the email I sent to the “journalist,” however.
Saxenda vs Mounjaro: A Comprehensive Comparison of Weight Loss Medications by John Mali.
He called Mounjaro, Saxenda, and described Mounjaro as the medication Qsymia.
FFS, how could jounalist get so much wrong when there is Google?
Here is the body of my letter to Mr. Mali.
You have the two medications in the article quite incorrect. And you are talking about three of them anyway, not two.
Mounjaro is a GLP-1/GIP
Mounjaro is NOT liraglutide, but tirzepatide.
From Eli Lilly: Mounjaro (tirzepatide) is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones.
Saxenda is a liraglutide, NOT a mix of the two medications phentermine
topiramate.
From Novo Nordisk: Saxenda® (liraglutide) injectionThe medication that combines those two medications is Qsymia.Qsymia is the medication that mixes phentermine and topiramate.Please correct the article!Barb Herrera
Terrific research by Barb !
Thank you!
Why, thank you!
Research is much of my jam. I have long been a research nerd. It’s so much fun learning a whole new slew of information about something that is personally relevant.
Thanks again!